Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Parrett

Plastic Surgery San Francisco, CA Medical Doctor

NPI 1023196557 CMS profile 46024

45 Castro St, San Francisco, CA 94114

Open in the dashboard

General payments

$11,503

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Parrett of San Francisco, CA is reported in the CMS Open Payments database as having received $11,503 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,592 41
2024 General $803 28
2023 General $1,054 32
2022 General $3,531 38
2021 General $1,554 23
2020 General $428 18
2019 General $2,540 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Parrett
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Brian Parrett were reported at $1,592. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Brian Parrett Plastic Surgery median Middle half National median
2019 $2,540 $371 $122–$1,483 $163
2020 $428 $158 $52–$438 $114
2021 $1,554 $249 $87–$752 $132
2022 $3,531 $274 $102–$793 $149
2023 $1,054 $299 $113–$891 $160
2024 $803 $361 $124–$1,062 $164
2025 $1,592 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $4,760 56 payments
  2. AbbVie, Inc. $2,131 78 payments
  3. Sientra, Inc. $1,541 15 payments
  4. KCI USA, Inc $904 2 payments
  5. Integra LifeSciences Corporation $553 15 payments
  6. Access Pro Medical, LLC $468 12 payments
  7. RTI Surgical, Inc $434 4 payments
  8. Aroa Biosurgery Incorporated $299 2 payments
  9. Musculoskeletal Transplant Foundation Inc. $142 1 payment
  10. AxoGen $130 5 payments
  11. Other $142 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,658 191 payments
  2. Consulting Fee $2,736 2 payments
  3. Travel and Lodging $1,109 2 payments
Products named General payments · program years 2019–2025
  1. ALLODERM $2,615 47 payments
  2. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,364 11 payments
  3. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,541 15 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $1,016 37 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $533 22 payments
  6. Matriderm $468 12 payments
  7. AMNIOEXCEL $398 13 payments
  8. INTEGRA DERMAL REGENERATION TEMPLATE $371 8 payments
  9. CORTIVA ALLOGRAFT DERMIS $277 2 payments
  10. PRIMATRIX $218 7 payments
  11. Other $2,584 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

123

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$795

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

0%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 51 $364
Mupirocin Generic 31 $236
Doxycycline Monohydrate Generic 16 $106
Triamcinolone Acetonide Generic 14 $53
Ciprofloxacin Hcl Generic 11 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 158 billing codes

Paid by Medicare

$472,379

Medicare's payments for the services billed

Medicare patients

552

Average age 73

Services billed

1,499

330 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 50%
Cancer 29%
Ischemic heart disease 26%
Diabetes 25%
Chronic kidney disease 24%
Depression 24%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record